The other investigators and clinical sites to participate in the trial are Dr. Donald Richards at The US Oncology Network, Tyler, TX, and Dr. Monica Mita at the Cedars-Sinai Medical Center in Los Angeles, CA.Dr. Jakob Dupont, Chief Medical Officer of OncoMed, commented, "The Wnt pathway has been an area of interest for breast cancer researchers for many years, and it is exciting to bring this novel Wnt targeting antibody, vantictumab, to the clinic to learn more about the safety and potential efficacy of the drug candidate in combination with paclitaxel in patients with advanced HER2 negative breast cancer."
OncoMed Pharmaceuticals Initiates First Phase 1b Clinical Trial Of First-in-Class WNT-Pathway-Targeting Antibody Vantictumab (OMP-18R5) With Paclitaxel In Breast Cancer
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts